Navigation Links
Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma

SAN DIEGO -- Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego.

The drug thalidomide achieved infamy in the early 1960s as the cause of severe birth defects after being given to pregnant mothers for morning sickness. However, this drug, along with the highly related compounds lenalidomide and pomalidomide, also help to treat blood cancers, and are used worldwide as a cornerstone of therapy for the bone marrow cancer multiple myeloma. These drugs modulate the immune system and together are called immunomodulators or IMiDs.

The exact mechanisms and targets through which these therapies work to enhance immune response or kill cancer cells have been largely unknown. As a result, knowing which patients to treat and how to separate out the positive properties of these drugs from side effects has been impossible.

After recent research identified a protein known as cereblon as a primary mediator of the birth defects caused by thalidomide, researchers theorized that cereblon may also orchestrate the anti-tumor properties and be the primary therapeutic target for multiple myeloma.

In this study, researchers tested the theory and found a possible link between resistance to IMiDs and presence of cereblon. The researchers then found that lowering the level of cereblon allows the IMiDs to work properly.

"Interestingly, some resistant patients had normal cereblon levels, suggesting that while cereblon may be an absolute requirement for response, there are likely other mechanisms present that play a role in drug resistance," says Dr. Stewart. "These findings help us understand which patients may be more or less likely to respond to therapy and allow us to focus on other ways we can target cereblon as a possible biomarker to improve treatment and patient outcomes in multiple myeloma. This work also suggests that we can begin to dissect out the cause of birth defects from the anti-cancer properties and develop safer drugs in the future."


Contact: Joe Dangor
Mayo Clinic

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
3. Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause
4. Mayo Clinic: Primary physicians may hold key to suicide prevention
5. Mayo Clinic: Short training course significantly improves detection of precancerous polyps
6. Mayo Clinic: Young women with rheumatoid arthritis at more risk for broken bones
7. Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes
8. ICU Patients at Risk for Rare Heart Rhythm Problem
9. Young patients with chronic illnesses find relief in acupuncture
10. For Some Breast Cancer Patients, Shorter Radiation Works Well
11. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a ... number even greater among Millennials (a whopping one in three aged 18 to 25 ... who are dissatisfied with their ink. In fact, RealSelf , the world’s largest ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... adjunctive imaging is the focus of numerous abstracts accepted for presentation here, at ... 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 01, 2015 ... announced the addition of the ... Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, ... report to their offering. --> ... addition of the "2016 Europe ...
(Date:12/1/2015)... ) has ... and Disposables Market by product, by Animal - ... offering. --> ) has announced ... Disposables Market by product, by Animal - Global ... --> Research and Markets ( ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: ... of chronic pain, announced today that the company will present ... held December 1-3 at the Luxe Sunset Boulevard Hotel in ... , CEO of Relmada Therapeutics, will present on Thursday, December ... . Please register at least 10 minutes ...
Breaking Medicine Technology: